PARP1 and cancer: This study shows the potential use of [18F]rucaparib or [18F]olaparib as PARP-targeting imaging agents to interrogate PARP expression levels during chemotherapy of cancer, aiding drug and radiation (bio-)dosimetry, treatment scheduling and gauging the emergence of resistance.